What treatment options are available for lurbinectedin induced anaphylaxis?

What causes anaphylaxis from lurbinectedin?

Lurbinectedin triggers anaphylaxis in some patients through an IgE-mediated hypersensitivity reaction. The drug binds to DNA minor groove sites and stops tumor cell transcription, but its chemical structure may provoke immune recognition and subsequent mast cell degranulation. Incidence rates remain low but are documented in clinical reports.

How do clinicians manage acute episodes?

Clinicians treat acute episodes of lurbinectedin anaphylaxis with standard protocols. Epinephrine 0.3–0.5 mg IM in the anterolateral thigh is the first-line intervention. Antihistamines such as diphenhydramine 25–50 mg IV or oral and corticosteroids like methylprednisolone 40–80 mg IV are added after epinephrine. Fluid resuscitation and oxygen support follow according to reaction severity.

What monitoring is needed after an acute reaction?

Patients who experience anaphylaxis from lurbinectedin must stay under observation for at least 4–6 hours. Biphasic reactions can occur at 4–8 hours after the initial peak, so extended monitoring captures delayed symptoms. Healthcare providers track vital signs, oxygen saturation, and airway status during this window.

Why are companies challenging this patent?

Lurbinectedin is still under patent protection in the United States through at least 2033. [1] Some competitors may already start planning generic launches or biosimilar equivalents once the exclusivity period ends. When does patent expire?

Lurbinectedin’s US patent expires in 2033. [1]